An observational study in Stereotactic Radiosurgery, Spinal Tumor and Radiomics, sponsored by Zhuang Hongqing. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-11.
Sponsored by Zhuang Hongqing · Observational
Among 14 studies in Spinal Cord Neoplasms with a site in China — 7 open to participants now, 7 under way, none of them phase 3. Spinal Cord Neoplasms · China.
Among the 14 studies in Spinal Cord Neoplasms with a site in China, this one is one of 3 that started in 2022, is one of 8 observational ones, and was the 7th registered.
105 studies on the registry are indexed under Spinal Cord Neoplasms; 27 are open to participants now.
Browse Spinal Cord Neoplasms studies →7 of the 14 studies in Spinal Cord Neoplasms with a site in China are open now. Recruiting first, the newest first:
Wei Xu · Sites in China
Ages 18+
Shanghai Changzheng Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Shengjing Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Beijing Tiantan Hospital · Sites in China
Ages 3–75
Peking University Third Hospital · Sites in China
Ages 18–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 23 Spinal Cord Neoplasms studies recruiting now, 15 (65%) set no upper age limit and 5 (22%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 150 across 31 observational studies indexed under Spinal Cord Neoplasms.
Median enrollment 103 across the 6 interventional studies, 125 across the 8 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Zhuang Hongqing as lead sponsor.
Zhuang Hongqing has 1 study filed under Spinal Cord Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Spinal Cord Neoplasms with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06587022Peking University Third HospitalDelineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors | 2026-12-30 |
| NCT07066475Beijing Tiantan HospitalA Registry-Based Cohort Study on the Clinical Outcomes of Spinal Cord Glioma Resection Via the Dorsolateral Sulcus Approach | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Spinal Cord Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to assess multimodal Radiomics-based prediction model for prognostic prediction in spinal tumors.
Sensitivity for prediction recurrence and survival of currently available prognostic scores is limited. This study proposes to establish a multimodal radiomics model for identifying tumor recurrence and prognostic prediction of spinal tumors. The study will investigate the relationship between the radiomics and the tumor microenvironment. The study includes the construction of multimodal radiomics-based prediction model and the validation of the prediction model.
Patients who had spinal tumors and completed CT, MRI, PET-CT examination before and after stereotactic radiosurgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A diagnosis of spinal tumors for which SBRT is appropriate Performance Status >60 of at least 3 months No to undergoing MR imaging Age >18 Complete the CT MRI or PET-CT examination before and after treatment Accept stereotactic radiosurgery
Exclusion Criteria:
Subjects unable to undergo MRI (includes non-MRI compatible material or devices and severe claustrophobia) Subjects with prior procedural intervention to the involved vertebral body that would result in artifact (kyphoplasty, screw and/or rod placement); minimally invasive surgery without instrumentation of the involved vertebral body and instrumentation immediately above or below the index lesion is allowed.
Subjects with spinal cord compression; minimally invasive "separation" surgery to first resect the epidural component is allowed Pregnant or breast-feeding women Allergy to standard IV contrast agents used in MRI
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who had spinal tumors and completed the CT, MRI or PET-CT examination before and after stereotactic radiosurgery.
Other: No interventions
As this is a prognosis evaluation study, there are no interventions.
PFS
progression-free survival
Time frame: 1 years
Overall survival (OS)
defined as the time from the beginning of diagnosis of spinal tumors to the death with any causes
Time frame: 1 years
ORR
objective response rate
Time frame: 3 months
DCR
disease control rate
Time frame: 3 months
Recurrence free survival (RFS)
defined as time between randomization and the time of any recurrence of ipsilateral chest, breast, regional lymph node recurrence, distant metastases, or death occurred
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2022; primary completion for Dec 2022, 6 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.